T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients

Lung Cancer

Volumn 84, Issue 3, 2014, Pages 295-300

  Li, Wei ^a   Ren, Shengxiang ^a   Li, Jiayu ^a   Li, Aiwu ^a   Fan, Lihong ^a   Li, Xuefei ^a   Zhao, Cao ^a   He, Yayi ^a   Gao, Guanghui ^a   Chen, Xiaoxia ^a   Li, Shuai ^a   Shi, Jingyun ^a   Zhou, Caicun ^a   Fei, Ke ^b   Schmid Bindert, Gerald ^c  

^a TONGJI UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acquired assistance; EGFR TKI; NSCLC; Secondary T790M mutation

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ICOTINIB; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; CROWN ETHER; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CERVICAL LYMPH NODE; CHINESE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SURVIVAL TIME; THORAX CANCER; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CROWN ETHERS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84901920866     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.03.011     Document Type: Article

References (35)

1. Brugger W., Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer 2012, 77(July (1)):2-8.
2. Gainor J.F., Shaw A.T. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013, 31(November (31)):3987-3996.
3. Pallis A.G., Syrigos K.N. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer 2013, 80(May (2)):120-130.
4. Tartarone A., Lazzari C., Lerose R., Conteduca V., Improta G., Zupa A., et al. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer 2013, 81(September (3)):328-336.
5. Ohashi K., Sequist L.V., Arcila M.E., Moran T., Chmielecki J., Lin Y.L., et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 2012, 109(July (31)):E2127-E2133.
6. Chen X., Zhang J., Hu Q., Li X., Zhou C. A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene. Lung Cancer 2013, 81(August (2)):308-310.
7. Yamaguchi N., Lucena-Araujo A.R., Nakayama S., de Figueiredo-Pontes L.L., Gonzalez D.A., Yasuda H., et al. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer 2014, 83(January (1)):37-43.
8. Watanabe S., Sone T., Matsui T., Yamamura K., Tani M., Okazaki A., et al. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma. Lung Cancer 2013, 82(November (2)):370-372.
9. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
10. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
11. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
12. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
13. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19:2240-2247.
14. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:26r-75r.
15. Takezawa K., Pirazzoli V., Arcila M.E., Nebhan C.A., Song X., de Stanchina E., et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012, 2:922-933.
16. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005, 102:7665-7670.
17. Hata A., Katakami N., Yoshioka H., Takeshita J., Tanaka K., Nanjo S., et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations. Cancer 2013, 119(24):4325-4332.
18. Oxnard G.R., Arcila M.E., Sima C.S., Riely G.J., Chmielecki J., Kris M.G., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.
19. Chaft J.E., Oxnard G.R., Sima C.S., Kris M.G., Miller V.A., Riely G.J. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011, 17(October (19)):6298-6303.
20. Sun J.M., Ahn M.J., Choi Y.L., Ahn J.S., Park K. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 2013, 82:294-298.
21. Sakai K., Horiike A., Irwin D.L., Kudo K., Fujita Y., Tanimoto A., et al. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci 2013, 104:1198-1204.
22. Yang J.J., Chen H.J., Yan H.H., Zhang X.C., Zhou Q., Su J., et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 2013, 79:33-39.
23. Inomata M., Shukuya T., Takahashi T., Ono A., Nakamura Y., Tsuya A., et al. Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. Anticancer Res 2011, 31:4519-4523.
24. Shukuya T., Takahashi T., Naito T., Kaira R., Ono A., Nakamura Y., et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer 2011, 74:457-461.
25. Ye X., Zhu Z.Z., Zhong L., Lu Y., Sun Y., Yin X., et al. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact. J Thorac Oncol 2013, 8:1118-1120.
26. Schmid-Bindert G., Wang Y., Jiang H., Sun H., Henzler T., Wang H., et al. EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients - a comparative study of three different minimal invasive sampling methods. PLoS ONE 2013, 8:e77948.
27. Ren S., Kuang P., Zheng L., Su C., Li J., Li B., et al. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys 2012, 64:155-160.
28. Ren S., Chen X., Kuang P., Zheng L., Su C., Li J., et al. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer 2012, 118:5588-5594.
29. Weickhardt A.J., Scheier B., Burke J.M., Gan G., Lu X., Bunn P.J., et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012, 7:1807-1814.
30. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
31. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
32. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(July (2)):123-132.
33. Janjigian Y.Y., Smit E.F., Horn L., Groen H.J.M., Camidge R., Gettinger S., et al. Activity of afatinib/cetuximab in patients (PTS) with EGFR mutation non-small cell lung cancer (NSCLC) and acquired resistance to EGFR inhibitors. Ann Oncol 2012, 23(9):401.
34. Ranson M., Pao W., Kim D.W., Kim S.W., Ohe Y., Felip E., et al. AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFRm+) and resistance (T790M) mutations in advanced NSCLC (ID 2289). J Thorac Oncol 2013, 8(Suppl. 2):S389.
35. Sequist L.V., Soria J.C., Gadgeel S., Wakelee H., Camidge D.R., Varga A., et al. First-in-human evaluation of CO-1686, an irreversible, highly, selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Thorac Oncol 2013, 8(Suppl. 2):S141-S142.